WEBSTER, Texas, April 28, 2011 /PRNewswire/ -- IDEV Technologies, Inc. (IDEV) today announced the firm has received approval from the Therapeutic Goods Administration (TGA), Australia's regulatory agency for medical drugs and devices, for the SUPERA VERITAS® stent system for use in biliary and peripheral procedures.
"We are pleased to receive the TGA approval, and look forward to launching SUPERA VERITAS in the Australian market later this year," said Christopher Owens, President and CEO of IDEV. "Australia represents a leading market in the Asia-Pacific region, and we have established a wholly owned subsidiary, IDEV Medical Technologies PTY LTD, in Sydney to support the product registration and introduction of this unique next generation technology. This is the first in a series of steps to extend our global footprint as well as our growth strategy in the Asia-Pacific region."
Australia represents an established growing peripheral vascular stent market, with an experienced base of endovascular physicians.
The SUPERA stent has been recognized as a different class of stent, based on proprietary technology and mechanical properties that result in unmatched radial strength and flexibility. It provides a new treatment option for patients with biliary strictures or peripheral arterial disease (PAD).
About IDEV Technologies, IncorporatedIDEV Technologies, Incorporated (IDEV) is an innovator and developer of next generation medical devices for use in interventional radiology, vascular surgery and cardiology. IDEV's worldwide headquarters is located in Webster, Texas and its European headquarters is located in Beuningen, The Netherlands. For more information please visit www.idevmd.com .
The SUPERA stent is currently indicated in the U.S. for the palliative treatment of biliary strictures produced by malignant neoplasms and in Europe, Canada and Australia for the